RET and thyroid gland carcinoma: Because the father (I-1) had a definite thyroid carcinoma history, there was a great possibility that these MEN2A patients got the mutation from the father's side (I-1) In our clinical practice, we disclosed a MEN2A patient ((II-2) without any symptoms by integrated DNA-based screening (RET proto-oncogene mutation analysis) / biochemical screening (calcitonin and catecholamine).